120410-24-4

120410-24-4 structure

Name: Biapenem
Chemical Name: biapenem
CAS Number: 120410-24-4
Molecular Formula: C₁₅H₁₈N₄O₄S
Molecular Weight: 350.393
Catalog: API Synthetic anti-infective drugs Antifungal drugs
Create Date: 2018-05-11 08:00:00
Modify Date: 2024-01-02 13:14:21
Biapenem is a parenteral carbapenem antibacterial agent with a broad spectrum.Target: AntibacterialBiapenem is a carbapenem antibiotic of in vitro antibacterial activity encompassing many Gramnegative and Gram-positive aerobic and anaerobic bacteria, including species producing β-lactamases. Biapenem is more stable than imipenem, mero-penem and panipenem to hydrolysis by human renal dihydropeptidase-I (DHP-I), and therefore does not require the coadministration of a DHP-I inhibitor. In randomised, nonblind or double-blind clinical trials, biapenem showed good clinical and bacteriological efficacy (similar to that of imipenem/ cilastatin) in the treatment of adult patients with intra-abdominal infections, lower respiratory infections or complicated urinary tract infections.

Name	biapenem
Synonyms	Biapenem (JAN/USAN) EINECS 204-352-8 5H-Pyrazolo[1,2-a][1,2,4]triazol-4-ium, 6-[[(4R,5S,6S)-2-carboxy-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl]thio]-6,7-dihydro-, inner salt BiapeneM Crude Biapenem [USAN:INN] (4R,5S,6S)-3-(6,7-Dihydro-5H-pyrazolo[1,2-a][1,2,4]triazol-4-ium-6-ylsulfanyl)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate [4R-[4a,5b,6b(R*)]]-6-[[2-Carboxy-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl]thio]-6,7-dihydro-5 H-pyrazolo[1,2-a][1,2,4]triazol-4-ium inner salt LJ C10627 omegacin MFCD00864863 Biapenem LJ C10,627 Biapenern L-627

Description	Biapenem is a parenteral carbapenem antibacterial agent with a broad spectrum.Target: AntibacterialBiapenem is a carbapenem antibiotic of in vitro antibacterial activity encompassing many Gramnegative and Gram-positive aerobic and anaerobic bacteria, including species producing β-lactamases. Biapenem is more stable than imipenem, mero-penem and panipenem to hydrolysis by human renal dihydropeptidase-I (DHP-I), and therefore does not require the coadministration of a DHP-I inhibitor. In randomised, nonblind or double-blind clinical trials, biapenem showed good clinical and bacteriological efficacy (similar to that of imipenem/ cilastatin) in the treatment of adult patients with intra-abdominal infections, lower respiratory infections or complicated urinary tract infections.
Related Catalog	Signaling Pathways >> Anti-infection >> Bacterial Research Areas >> Infection
References	[1]. Perry, C.M. and T. Ibbotson, Biapenem. Drugs, 2002. 62(15): p. 2221-34; discussion 2235. [2]. Kasahara, S., et al., [Clinical effects of biapenem on febrile neutropenia in patients with hematological malignancy]. Jpn J Antibiot, 2008. 61(3): p. 115-21.

RIDADR	NONH for all modes of transport

93711-81-0

120410-24-4

104873-15-6

120410-24-4

120764-68-3

120410-24-4

Precursor 2
104873-15-6 120764-68-3
DownStream 0